Hot Features
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb t... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -8.33333333333 | 0.06 | 0.06 | 0.05 | 5981 | 0.05446501 | CS |
| 4 | 0 | 0 | 0.055 | 0.06 | 0.04 | 34002 | 0.0542216 | CS |
| 12 | -0.025 | -31.25 | 0.08 | 0.08 | 0.04 | 34418 | 0.06189389 | CS |
| 26 | -0.03 | -35.2941176471 | 0.085 | 0.11 | 0.04 | 64138 | 0.08287497 | CS |
| 52 | -0.065 | -54.1666666667 | 0.12 | 0.16 | 0.04 | 116490 | 0.09577651 | CS |
| 156 | -0.065 | -54.1666666667 | 0.12 | 0.425 | 0.035 | 142501 | 0.12884851 | CS |
| 260 | -0.225 | -80.3571428571 | 0.28 | 0.425 | 0.035 | 115148 | 0.15388194 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.